Zentalis Pharmaceuticals Inc

Executive option buys at Zentalis signal confidence in its Azenosertib pipeline, yet investors should watch clinical milestones and regulatory outcomes before betting on the stock.

Walters Group’s 13 % stake in Zentalis signals confidence in its KRAS G12C drug Azenosertib, a Phase‑2 success that could boost the stock past $3 if FDA milestones are hit.